已收盤 09-19 16:00:00 美东时间
+0.010
+0.61%
Roth MKM analyst Jonathan Aschoff maintains BioRestorative Therapies (NASDAQ:BRTX) with a Buy and raises the price target from $15 to $18.
08-14 22:52
BioRestorative Therapies (BRTX) just unveiled an update. The latest press relea...
08-14 09:17
BioRestorative Therapies press release (NASDAQ:BRTX): Q2 GAAP EPS of -$0.50 beats by $0.05. Cash used in operating activities in the second quarter of 2024 was $1.9 million. The Company ended the seco...
08-14 04:57
BioRestorative Therapies (NASDAQ:BRTX) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.55) by 9.09 percent.
08-14 04:09
BioRestorative Therapies (BRTX) has shared an update. Discover the latest updat...
08-07 05:18
Analyst Michael Okunewitch of Maxim Group maintained a Buy rating on BioRestora...
06-15 03:45
U.S. stocks traded mixed toward the end of trading, with the S&P 500 edging...
06-14 02:35
Gainers Longeveron (NASDAQ:LGVN) stock increased by 74.6% to $3.16 during Thur...
06-14 00:31
U.S. stocks traded mixed midway through trading, with the Dow Jones index dippi...
06-14 00:07
BioRestorative Therapies (NASDAQ:BRTX) traded ~20% higher in the premarket Thursday after the New York-based biotech said it has engaged in talks with a commercial-stage company to license IP rights r...
06-13 20:01